Clearstead Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Clearstead Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$599	Buy	+7	New	+$730	﹤0.01%	2805

Other funds holding MIRM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Clearstead Advisors's MIRM Position: Q3 2026 in Review

Clearstead Advisors opened a new position in Mirum Pharmaceuticals (MIRM) in Q3 2026: 7 shares worth $599. The stake represents ﹤0.01% of the portfolio and ranks #2805 among its holdings.

128 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

Clearstead Advisors held 7 shares of Mirum Pharmaceuticals worth $599 as of Q3 2026.
Mirum Pharmaceuticals was a new Clearstead Advisors position in Q3 2026.
Mirum Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #2805 holding.
128 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.